Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2025-05-12 Investor Presentation
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Q2 Investor Webinar 30 May 2025 2 pages 251.9KB
Investor Presentation Classification · 90% confidence The document is an announcement dated 13 May 2025 from PYC Therapeutics Limited about an upcoming investor webinar scheduled for 30 May 2025. It provides details about the webinar, including registration information, and describes the company's drug development programs and clinical trial progress. There are no financial statements, detailed financial analysis, or comprehensive report content present. The document is relatively short (5261 characters) and serves as an invitation and update rather than a full financial or management report. It does not contain earnings data, audit information, or regulatory certifications. It is clearly an announcement of an event (investor webinar) rather than a report or transcript of the event. Therefore, the most appropriate classification is Investor Presentation (IP), as it is a detailed presentation for investors focusing on company progress and strategy, albeit in announcement form. The confidence is high given the clear nature of the content and format.
2025-05-12 English
Foundation Fighting Blindness Presentation Materials 25 pages 2.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation of clinical trial results and scientific data related to PYC Therapeutics' VP-001 treatment for Retinitis Pigmentosa type 11. It includes information about the company, clinical trial phases, patient cohorts, safety outcomes, and efficacy signals. The document is titled as presentation materials for the Foundation Fighting Blindness Retinal Therapeutics Innovation Summit dated May 2, 2025. It is not an official financial report, earnings release, regulatory filing, or announcement of voting results. The content is consistent with an investor or scientific presentation focusing on clinical and strategic information for investors and stakeholders. Therefore, the document best fits the category of Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-05-01 English
Presentation of Clinical Proof of Concept in Lead Program 9 pages 898.2KB
Investor Presentation Classification · 95% confidence The document is a detailed announcement from a pharmaceutical company about clinical trial results for a drug candidate (VP-001) targeting a specific eye disease. It includes extensive data on efficacy, safety, and patient impact, with references to clinical endpoints, statistical significance, and upcoming regulatory meetings with the FDA. The content is focused on presenting clinical proof of concept and trial data rather than a brief earnings summary or a regulatory filing. It is not a full annual or interim financial report, nor is it a transcript of a call or a governance or management change announcement. The document is a comprehensive presentation of clinical trial results and scientific data intended for investors and stakeholders, fitting the profile of an Investor Presentation (IP). The length (15,000 characters) and detailed data support this classification rather than a short announcement or a regulatory filing.
2025-04-27 English
Change in substantial holding 3 pages 259.3KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, specifically a "Notice of change of interests of substantial holder." It details changes in voting power and relevant interests of a substantial shareholder in PYC Therapeutics Limited, including dates, share counts, and nature of changes such as entitlement issues and dilution. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is 8398 characters long, contains detailed data on shareholding changes, and is not merely an announcement or certification. Therefore, it fits the Major Shareholding Notification category.
2025-04-27 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 547.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q1 2025 SHAREHOLDER UPDATE' and contains detailed financial information including cash flow statements, cash on hand, payments to related parties, and financing activities for the quarter ended 31 March 2025. It references an Appendix 4C, which is a quarterly cash flow report required by the Australian Securities Exchange (ASX) for entities subject to Listing Rule 4.7B. The document includes substantive financial data and analysis for a period shorter than a full fiscal year (the first quarter of 2025). It is not merely an announcement or a brief summary but contains actual financial statements and operational updates. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-23 English
Application for quotation of securities - PYC 5 pages 16.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the number and type of securities to be quoted, references a previous Appendix 3B announcement for the issue of securities, and provides information about the issued capital following the quotation. This is a regulatory announcement related to capital markets and securities quotation, not a financial report or earnings release. It is not a report publication announcement since it contains substantive details about the securities to be quoted. The document fits the category of Share Issue/Capital Change announcements, which cover new share issues and capital changes.
2025-04-22 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.